Objective: To investigate the effects of Ruanganning on fibrosis level in in rats with liver fibrosis. Method: Sixty rats were randomly divided into six groups: the normal group

the model group

bifendate group(0.01 g·L-1)

high Ruanganning group(0.12 g·kg-1)

middle Ruanganning group(0.06 g·kg-1) and low Ruanganning group(0.03 g·kg-1). The treatment groups were orally administered once per day for six weeks

whereas the normal and model groups were orally administered with saline. Six weeks later

the blood simple was collected for the examination of alanine aminotransferase(ALT)

aspartate aminotransferase(AST)

albumin(ALB)

hyaluronic acid(HA)

Laminin(LN)

precollagen typeⅢ(PCⅢ)

hydroxyproline (HYP) and liver specimen were collected for the observation of pathology. Result: Compared with model group

Ruanganning could protect hepatic function. Following the treatment with Ruanganning

ALT and AST activities were significantly reduced and ALB activity was obviously increased in treating group(P<0.05

P<0.01)

especially the middle and high doses could significantly degrade the serum levels of HA

LN

PCIII and the exorbitant HYP in liver tissue(P<0.05

P<0.01). Furthermore

pathological examination indicates Ruanganning can protect rats from hepatic fibrosis. Conclusion: Ruanganning can greatly protect from liver fibrosis in rats induced by CCl4.